The company said revenue from operations for the second quarter ended September 2025 stood at Rs 14,405.22 crore, reflecting an 8.6% rise YoY compared to Rs 13,264.22 crore reported in the September 2024 quarter.
Sun Pharma reported EBITDA of Rs 4,527.1 crore for Q2 FY26, marking a 14.9% rise from the same period last year. The EBITDA margin stood at 31.3%. Profit before exceptional items and tax rose 15.8% to Rs 4,167.6 crore.
Sales from the Global Innovative Medicines segment stood at $333 million, up 16.4% YoY, accounting for 20.2% of total revenue. The company said U.S. sales of Innovative Medicines surpassed Generics for the first time during the quarter.
Meanwhile, the company said its research and development investment for the quarter stood at Rs 782.7 crore, or 5.4% of sales.
Kirti Ganorkar, Managing Director of Sun Pharma, said, “India, Emerging Markets and Rest of World led our growth for the period. U.S. sales of Innovative Medicines have surpassed Generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability.”
Sun Pharna H1 performance
For the first half of FY26, consolidated sales stood at Rs 28,191.3 crore, a growth of 9.3% over the same period last year. EBITDA rose 17% to Rs 8,828.7 crore, with margins at 31.2%.Adjusted net profit (excluding exceptional items) was Rs 6,114.1 crore, up 4.1% YoY, while R&D investment came in at Rs 1,685.5 crore, or 6% of sales.
More to come…